Market launch in Q1/2008

BAD VILBEL, Germany | December 19, 2007 | STADA received, as expected, in the scope of an EU-wide approval process for Erythropoietin-zeta (Epo-zeta), the approval for the treatment of anaemia associated with chronic renal failure and chemotherapy from the EU Commission.

Thus, in the scope of a sales license granted by BIOCEUTICALS Arzneimittel AG, STADA will be able to market Epo-zeta in Germany under the brand name Silapo® in the first quarter of 2008 via the Group-owned sales company cell pharm GmbH. Due to further license agreements, Hospira, Inc., a U.S.-based global specialty pharmaceutical and medication delivery company, as is known, will be able to market Epo-zeta in the EU under the brand name Retacrit™ from the first quarter of 2008.

SOURCE: STADA

---